Dasatinib inhibits TGFβ-induced myofibroblast differentiation through Src-SRF Pathway.
about
Imatinib and dasatinib as salvage therapy for sclerotic chronic graft-vs-host diseaseNovel roles of Src in cancer cell epithelial-to-mesenchymal transition, vascular permeability, microinvasion and metastasis.Nintedanib reduces ventilation-augmented bleomycin-induced epithelial-mesenchymal transition and lung fibrosis through suppression of the Src pathway.Sustained activation of the AKT/mTOR and MAP kinase pathways mediate resistance to the Src inhibitor, dasatinib, in thyroid cancer.
P2860
Dasatinib inhibits TGFβ-induced myofibroblast differentiation through Src-SRF Pathway.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Dasatinib inhibits TGFβ-induced myofibroblast differentiation through Src-SRF Pathway.
@ast
Dasatinib inhibits TGFβ-induced myofibroblast differentiation through Src-SRF Pathway.
@en
type
label
Dasatinib inhibits TGFβ-induced myofibroblast differentiation through Src-SRF Pathway.
@ast
Dasatinib inhibits TGFβ-induced myofibroblast differentiation through Src-SRF Pathway.
@en
prefLabel
Dasatinib inhibits TGFβ-induced myofibroblast differentiation through Src-SRF Pathway.
@ast
Dasatinib inhibits TGFβ-induced myofibroblast differentiation through Src-SRF Pathway.
@en
P2093
P2860
P1476
Dasatinib inhibits TGFβ-induced myofibroblast differentiation through Src-SRF Pathway.
@en
P2093
Erin Gurley
Jessica Ujjin
LeeAnn Thompson
Maha Abdalla
Payaningal R Somanath
Robert Newsome
Samantha Burke
P2860
P304
P356
10.1016/J.EJPHAR.2015.11.008
P407
P577
2015-11-05T00:00:00Z